S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
S&P 500   4,549.34 (-0.39%)
DOW   36,054.43 (-0.19%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Eloxx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELOX)

$1.10
-0.01 (-0.90%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.10
$1.12
50-Day Range
$1.07
$4.91
52-Week Range
$0.95
$10.90
Volume
2,584 shs
Average Volume
436,871 shs
Market Capitalization
$3.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.00

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,900.0% Upside
$55.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.91) to ($7.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars


ELOX stock logo

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

ELOX Stock Price History

ELOX Stock News Headlines

Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Eloxx Pharmaceuticals Inc ELOX
Eloxx Pharmaceuticals prices $2M stock offering
Eloxx Pharmaceuticals Announces Registered Direct Offering - Quick Facts
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Eloxx Pharmaceuticals (NASDAQ: ELOX)
See More Headlines
Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELOX
Employees
18
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$55.00
High Stock Price Target
$55.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+4,810.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.92) per share

Miscellaneous

Free Float
2,508,000
Market Cap
$3.52 million
Optionable
Not Optionable
Beta
2.65
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














ELOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eloxx Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELOX shares.
View ELOX analyst ratings
or view top-rated stocks.

What is Eloxx Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they expect the company's share price to reach $55.00 in the next year. This suggests a possible upside of 4,900.0% from the stock's current price.
View analysts price targets for ELOX
or view top-rated stocks among Wall Street analysts.

How have ELOX shares performed in 2023?

Eloxx Pharmaceuticals' stock was trading at $1.82 at the beginning of 2023. Since then, ELOX stock has decreased by 39.6% and is now trading at $1.10.
View the best growth stocks for 2023 here
.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its earnings results on Monday, November, 13th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.66.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?

1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends
.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELOX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -